Select Medical (SEM) Q4 2025: Outpatient Margin Slides to 3.4% as Payer Mix and Health Costs Pressure Results
Outpatient rehab margin collapse and health insurance cost spikes defined Select Medical’s Q4, offsetting robust inpatient rehab expansion. Management’s guidance banks on a rebound in outpatient and continued pipeline execution, but margin volatility and payer mix shifts remain critical watchpoints for 2026.
Summary
- Margin Pressure Intensifies: Outpatient rehab faced a dramatic margin drop from payer mix headwinds and health insurance costs.
- Inpatient Rehab Drives Growth: New bed additions and occupancy gains in rehab hospitals remain the company’s core growth engine.
- 2026 Hinges on Outpatient Recovery: Management’s outlook relies on outpatient stabilization and regulatory reimbursement tailwinds.
Performance Analysis
Select Medical’s Q4 results were marked by a sharp divergence across business segments. The inpatient rehabilitation facility (IRF, acute rehab hospitals) segment delivered over 15% revenue growth and 11% adjusted EBITDA growth, with occupancy and census both rising. This division now operates at over 20% margin, though new facility startup losses trimmed the consolidated margin year-on-year.
In contrast, the outpatient rehab segment saw a significant deterioration. Revenue per visit fell to $98 from $102, driven by a combination of lower Medicare rates, a less favorable payer mix, and higher managed care discounts. The segment’s margin plummeted to 3.4% from 8.3% a year ago, with executives attributing $11 million of the hit to one-time health insurance and variable discount expenses, and another $4 million to broader company-wide health cost inflation. The critical illness recovery hospital segment (LTACH, long-term acute care hospitals) posted stable results, with flat occupancy and a steady 10.5% margin.
- Outpatient Rehab Margin Collapse: Margin fell to 3.4% as payer mix, managed care discounts, and health insurance costs converged.
- IRF Expansion Offsets Weakness: Inpatient rehab occupancy rose to 82%, and new beds drove nearly 10% census growth.
- Critical Illness Segment Holds Steady: Admissions and margins in LTACH remained consistent, aided by stable labor costs.
Cash flow from operations reached $64.3 million, but rising health costs and outpatient softness weighed on consolidated profitability. Management’s guidance for 2026 assumes outpatient headwinds are largely transitory, with regulatory reimbursement increases expected to assist margin recovery.
Executive Commentary
"A contributing factor to the decline in adjusted EBITDA was an increase in health insurance expense year over year, driven by elevated health-related costs, including higher cost claimants, increased utilization of medical and pharmacy benefits, and cost escalation."
Thomas Mullen, Chief Executive Officer
"We believe that the $11 million that we just alluded to were truly one-timers. And then for Critical illness, you know, the fourth quarter, you know, we basically were kind of right in plan or maybe even a little better than we expected. And for critical illness, you know, again, I would say cautiously optimistic for next year."
Michael Malatesta, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Inpatient Rehab as Core Growth Platform
Inpatient rehabilitation hospitals remain Select Medical’s strategic focus, with 399 new beds slated for 2026 and 2027. The company continues to leverage joint ventures with health systems (e.g., Cleveland Clinic, Baylor Scott & White, Banner Health) to expand footprint and occupancy. Management cited a robust development pipeline and rising census as evidence of sustainable demand, positioning IRF as the company’s margin anchor.
2. Outpatient Rehab Under Scrutiny
The outpatient rehab segment is undergoing operational triage, as margin erosion from payer mix deterioration, Medicare rate cuts, and legacy receivable write-offs exposed structural vulnerabilities. Leadership flagged targeted efforts to address staffing, rate negotiations, and market-specific challenges. Recovery in this segment is pivotal for consolidated margin improvement in 2026.
3. Cost Structure and Health Insurance Volatility
Unexpected health insurance cost spikes revealed exposure to self-insured medical benefit volatility, with $15 million in unanticipated Q4 expense. Management characterized this as a one-off event, but the scale of the impact highlights risk in cost forecasting and the need for tighter claims management or risk pooling strategies.
4. Capital Allocation on Hold Amid Take Private Review
The board is evaluating a take private proposal from the executive chairman, pausing share repurchases and other discretionary capital moves. CapEx remains focused on IRF expansion, with $200–$220 million planned for 2026. Dividend policy is unchanged, but strategic flexibility is limited until the review process concludes.
5. AI and Operational Efficiency Initiatives
AI adoption is in early stages, with pilots underway for back-office billing automation and outpatient collections. Management also flagged future potential for clinical AI applications (e.g., virtual sitters, telemetry monitoring), but these are not yet material to the near-term cost structure or margin profile.
Key Considerations
Q4 exposed both the strengths and vulnerabilities of Select Medical’s diversified post-acute model. The company’s ability to execute on IRF expansion and navigate payer mix headwinds in outpatient will determine its margin trajectory and capital allocation flexibility in 2026.
Key Considerations:
- Margin Sensitivity to Health Costs: Health insurance expense volatility can materially impact consolidated EBITDA, underscoring the importance of claims management and forecasting accuracy.
- Payer Mix and Reimbursement Risk: Outpatient segment’s exposure to Medicare and managed care rate changes remains a structural challenge, especially as payer mix shifts toward less profitable populations.
- Labor and Staffing Dynamics: IRF and LTACH segments benefit from stabilized labor costs, but outpatient therapist recruitment remains a headwind in select markets.
- Development Pipeline Execution: Timely delivery of new IRF beds is essential to offsetting margin pressures elsewhere and sustaining growth.
- Capital Flexibility Limited by Strategic Review: The ongoing take private process constrains buybacks and may influence future capital deployment priorities.
Risks
Key risks for Select Medical include ongoing payer mix deterioration in outpatient rehab, unexpected health insurance cost spikes, and execution risk in new facility ramp-up. Regulatory changes, such as Medicare reimbursement adjustments, could swing margins positively or negatively, while the outcome and timing of the take private process introduce further uncertainty around capital allocation and strategic direction. Persistent labor shortages or union activity, though currently stable, could re-emerge as sector-wide wage pressure builds.
Forward Outlook
For Q1 2026, Select Medical guided to:
- Revenue of $5.6 billion to $5.8 billion for the full year
- Adjusted EBITDA of $520 million to $540 million
- EPS of $1.22 to $1.32
- CapEx of $200 million to $220 million
For full-year 2026, management maintained guidance, emphasizing:
- Outpatient segment recovery is expected as recent cost spikes are viewed as one-time events and Medicare rate increases take effect
- IRF division remains the primary growth driver, with robust pipeline and stable margins despite startup losses
Takeaways
Investors should focus on margin stabilization and outpatient segment recovery as the linchpins for 2026 performance.
- Margin Compression Highlighted Structural Weakness: Q4 exposed how cost spikes and payer mix can quickly erode profitability, especially in outpatient rehab.
- IRF Remains the Margin and Growth Anchor: Continued occupancy gains and new bed openings are critical to offsetting volatility elsewhere.
- Watch for Outpatient Rebound and Capital Allocation Shifts: The pace of outpatient recovery and resolution of the take private review will drive valuation and strategic flexibility in the coming quarters.
Conclusion
Select Medical’s Q4 revealed both the resilience of its inpatient rehab strategy and the vulnerability of its outpatient model to margin shocks. The company’s 2026 trajectory depends on successful execution in IRF, stabilization in outpatient, and disciplined cost management amid capital allocation uncertainty.
Industry Read-Through
SEM’s quarter underscores the sector-wide risk of payer mix shifts and health cost volatility in post-acute and outpatient care. The sharp margin compression in outpatient rehab highlights the challenge of navigating reimbursement pressure and labor constraints, a theme likely to persist for peers with similar exposure. The IRF segment’s robust growth and joint venture model reinforce the value of health system partnerships and scale in driving occupancy and margin stability. Ongoing capital allocation constraints due to strategic reviews may become more common as private equity and founder-led takeovers proliferate in healthcare services.